Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TARA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Choline Chloride | Choline Deficiency | Phase 2/3 · NCT06910943 | Recruiting |
| Investigator's Choice of Intravesical… | Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 · NCT07480356 | Recruiting |
| Lyophilized Inactivated Group A Streptococcus… | Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 · NCT07480356 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TARA holds $143.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.9M/quarter from operations, an estimated runway of 25.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TARA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 4,696,709 | 7.63% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,387,459 | 5.50% | 2026-03-31 |
| Millennium Management LLC | 5%+ holder (13G) | 3,201,936 | 5.20% | 2026-07-01 |
| Jesse Shefferman CEO and President, Director · +665,313 options |
Insider | 991,832 | 1.61% | 2026-06-29 |
| Jacqueline Zummo Chief R&D Officer · +180,000 options |
Insider | 94,827 | 0.15% | 2026-04-08 |
| Leonardo Viana Nicacio Chief Medical Officer · +158,000 options |
Insider | 78,181 | 0.13% | 2026-01-16 |
| William Conkling Chief Commercial Officer · +358,000 options |
Insider | 69,992 | 0.11% | 2026-06-02 |
| Patrick Fabbio Chief Financial Officer · +175,000 options |
Insider | 64,115 | 0.10% | 2026-01-26 |
| Richard S Levy Director · +55,000 options |
Insider | 51,000 | 0.08% | 2025-05-14 |
| Hannah Fry VP, Controller · +55,000 options |
Insider | 42,723 | 0.07% | 2026-01-26 |
Share count 61,570,351 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TARA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →